🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the battle against increasingly resistant strains of the pathogen, according to scientists.

An International Health Concern

The sexually transmitted infection are escalating around the world, with figures suggesting in excess of 82 million infections each year. Notably increased rates are observed in the African continent and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune advancement in the context of increasing worldwide cases, escalating drug resistance and the highly restricted available drugs presently on offer.”

Medical experts are particularly alarmed about the increase in drug-resistant strains. The WHO has designated it as a "high-priority threat". Ongoing monitoring revealed that the effectiveness of primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Secure Authorization

Zoliflodacin, also known as Nuzolvence, was cleared by the American regulatory agency in December for use against gonorrhoea. This STI can lead to significant complications, including infertility. Researchers hope that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in the same week. This medication, which is employed against UTIs, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

This new treatment stemmed from a new, not-for-profit approach for medication research. The non-profit organisation GARDP collaborated with the pharmaceutical company its industry partner to develop it.

“This milestone represents a huge turning point in the treatment of highly resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Testing Results and Global Access

Based on results detailed in a prominent scientific publication, the new drug eradicated the vast majority of genital gonorrhoea infections. This establishes an comparable level with the existing first-line therapy, which combines an injection and a pill. The study included over 900 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the rights to register and commercialise the drug in a wide range of developing nations.

Clinicians directly involved have expressed positive views. Having a easy-to-administer therapy like this is hailed as a "revolutionary step" for public health efforts. This is deemed crucial to reduce the burden of the disease for patients and to prevent the spread of highly drug-resistant gonorrhoea around the world.